By Fineline Cube 
AstraZeneca plc (NYSE: AZN) announced financial results for the second quarter and first half of 2026, delivering USD 15.384 billion in Q2 total revenue, representing 5% year-on-year growth at constant exchange rates (CER). The company reported USD 3.164 billion in operating profit and USD 5.158 billion in Core operating profit, up 10% year-on-year.
Financial Highlights – H1 2026
| Metric | H1 2026 Result | YoY Change (CER) |
|---|---|---|
| Total Revenue | USD 30.672 billion | +6% |
| Core Operating Profit | Not disclosed | Not disclosed |
| Full-Year 2026 Guidance | Mid-to-high single-digit % growth | On track |
| 2030 Revenue Target | USD 80 billion | Progress maintained |
Regional Performance – H1 2026
| Region | Revenue | YoY Change (CER) |
|---|---|---|
| United States | USD 12.89 billion | +8% |
| Emerging Markets (ex-China) | USD 4.809 billion | +10% |
| China | USD 3.51 billion | -5% |
| Europe | USD 6.822 billion | +8% |
Therapy Area Performance – H1 2026
| Therapy Area | Revenue | YoY Change (CER) | Key Drivers |
|---|---|---|---|
| Oncology | USD 14.123 billion | +15% | Tagrisso (osimertinib), Imfinzi (durvalumab) + Imjudo (tremelimumab) |
| Respiratory & Immunology (R&I) | USD 4.75 billion | +9% | Not specified |
| Rare Disease | USD 4.911 billion | +11% | Not specified |
| Cardiovascular, Renal and Metabolism (CVRM) | USD 6.013 billion | -12% | Farxiga exclusivity loss in US, VBP in China |
Oncology Product Highlights
- Tagrisso (osimertinib): USD 3.775 billion (+6%)
- Imfinzi (durvalumab): USD 3.548 billion (+29%)
- Imjudo (tremelimumab): USD 160 million (-7%)
Pipeline Update – PACIFIC-8 Trial Discontinuation
Following the discontinuation of several pivotal Phase III trials for Gilead and Arcus Biosciences’ anti-TIGIT inhibitor domvanalimab—due to failing primary survival endpoints or futility analyses—AstraZeneca has discontinued patient recruitment into the PACIFIC-8 Phase III trial.
The trial evaluated Imfinzi in combination with domvanalimab versus Imfinzi alone in patients with PD-L1 positive Stage III unresectable non-small cell lung cancer (NSCLC). No new safety signals were observed in PACIFIC-8.
Strategic Outlook
- Growth Drivers: Double-digit growth in Oncology and Rare Disease successfully offset headwinds from Farxiga’s loss of exclusivity in the US and volume-based procurement (VBP) in China.
- Geographic Resilience: Strong performance in US (+8%), Europe (+8%), and Emerging Markets ex-China (+10%) partially compensated for China decline (-5%).
- Long-term Vision: Company remains on track to deliver its ambition of USD 80 billion in total revenue by 2030.
Forward‑Looking Statements
This brief contains forward-looking statements regarding financial performance, pipeline development, and strategic objectives. Actual results may differ due to risks including competitive dynamics, regulatory decisions, market access challenges, and clinical trial outcomes.-Fineline Info & Tech